Amit Sanyal, MD: A Clinician’s Perspective

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Sep

Today In Oncology

Amit Sanyal, MD: A Clinician’s Perspective

Related Videos

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Deborah Collyar: What's In It for Patients?

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Losing Weight and Breast Cancer Risk? The GLP-1 Question

TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer

Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer

NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer